<DOC>
	<DOCNO>NCT01245634</DOCNO>
	<brief_summary>This randomized double-blind , placebo-controlled study evaluate efficacy safety RO4905417 prevention saphenous vein graft disease patient undergo elective urgent coronary artery bypass ( CABG ) surgery . Patients randomize receive either RO4905417 20 mg/kg intravenous infusion placebo every 4 week 32 week .</brief_summary>
	<brief_title>A Study RO4905417 Patients Undergoing Coronary Artery Bypass Graft ( CABG ) Surgery</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Graft Occlusion , Vascular</mesh_term>
	<criteria>Adult patient , &gt; 18 &gt; 85 year age Patients undergoing primary multivessel CABG least one saphenous vein graft . without cardiopulmonary bypass Body mass index ( BMI ) &lt; /= 35 kg/m2 Participation previous study evaluate RO4905417 Positive HIV , receive antiretroviral drug , immunosuppressed Acute infection screen active chronic infection within 3 month prior CABG surgery Patients undergoing emergency cardiac surgery immediately lifethreatening condition Patients undergo concomitant valve surgery History CABG ( patient without prior CABG surgery admit study ) Left ventricular ejection fraction &lt; 20 % History transient ischemic attack stroke within 12 week prior CABG procedure Significant renal liver impairment Malignancy diagnose within previous 5 year ( except successfully resect basal cell cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>